- Conditions
- Ovarian Neoplasms
- Interventions
- AMG 479
- Biological
- Lead sponsor
- Translational Research in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 16
- States / cities
- Bakersfield, California • Fullerton, California • La Verne, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 82
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type1 Diabetes Mellitus, Diabetes Mellitus, Type 1, Autoimmune Diabetes, Juvenile Diabetes, Diabetes Mellitus Complication, Diabetic Nephropathies, Metabolic Disease, Diabetic Kidney Disease
- Interventions
- Blood draw, Urine sample collection, DXA scan
- Diagnostic Test
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
- Interventions
- Deucrictibant low dose, Deucrictibant high dose, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri
- Conditions
- Cancer
- Interventions
- DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
- Genetic · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 1 Diabetes
- Interventions
- HIGH error, NO error, LOW error
- Device
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infection, Nematode Infection, Strongyloidiasis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 80 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1989
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Type I Diabetes Mellitus
- Interventions
- Glutamine, Placebo
- Dietary Supplement
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Hereditary Angioedema
- Interventions
- KVD900 600 mg, KVD900 300 mg
- Drug
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
- Interventions
- insulin aspart, inhaled human insulin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 9
- States / cities
- Fresno, California • New Orleans, Louisiana • Kansas City, Missouri + 6 more
- Conditions
- Type I Hypersensitivity
- Interventions
- RagweedMATAMPL
- Biological
- Lead sponsor
- Allergy Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 4
- States / cities
- Novi, Michigan • Minneapolis, Minnesota • Asheville, North Carolina + 1 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- SI-Informed Bolus Calculator
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Diabetes Mellitus, Type 1, Autoimmune Diseases, Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders, Immune System Diseases, Metabolic Diseases
- Interventions
- Glutamine vs. Placebo, Exercise
- Drug · Behavioral
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Maridebart cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Multiple Myeloma
- Interventions
- Not listed
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- No City Provided, New Jersey
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
- Interventions
- Rina-S, Carboplatin, Bevacizumab, Pembrolizumab
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 884 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
- Conditions
- Hereditary Angioedema, HAE, Prophylaxis
- Interventions
- BCX7353
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 387 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 39 more
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, Colorectal Cancer, MTOR Activating Mutation
- Interventions
- Nab-Rapamycin, Nivolumab
- Drug · Biological
- Lead sponsor
- Sarcoma Oncology Research Center, LLC
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Peanut Allergy
- Interventions
- Whole peanut extract, Placebo formulation
- Biological
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 6 Years to 50 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
- Conditions
- Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
- Interventions
- Hyperinsulinemic, euglycemic clamp, 20% dextrose
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 13 Years to 51 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hereditary Angioedema
- Interventions
- KVD900 600 mg, Drug: KVD900 300 mg
- Drug
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
- Conditions
- Diabetes Type 1
- Interventions
- Not listed
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Acute Myocardial Infarction, Acute Coronary Syndrome
- Interventions
- high-sensitivity cardiac troponin testing
- Diagnostic Test
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type I Hypersensitivity
- Interventions
- Grass MATA MPL
- Biological
- Lead sponsor
- Allergy Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
- Interventions
- Sparsentan
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more